Minerva Surgical Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Darrin Hammers

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	1.6yrs

Actualizaciones recientes de la dirección

Recent updates

Is There An Opportunity With Minerva Surgical, Inc.'s (NASDAQ:UTRS) 44% Undervaluation?

Aug 11

Minerva downgraded at JPMorgan citing lowered guidance

Aug 10

Minerva Surgical, Inc. (NASDAQ:UTRS) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 10

Minerva Surgical - Uterine Play For Sale

Nov 02

CEO

Darrin Hammers

less than a year

Permanencia

Mr. Darrin Hammers is Chief Executive Officer of Minerva Surgical, Inc. from August 2024. He has certain years of leadership experience in the medical device industry and he has been President and Chief Ex...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Darrin Hammers	Chief Executive Officer	less than a year	sin datos	sin datos
Greg Simbro	Vice President of Finance	less than a year	sin datos	sin datos
Erik Reese	Vice President of Sales	less than a year	sin datos	sin datos
Wendy Bowman	Vice President of Human Resources	no data	sin datos	0.016% $ 0.001
Evgueni Skalnyi	Chief Medical Officer	1.7yrs	US$388.99k	sin datos
Joanne Long	Vice President of Corporate Controller	3.6yrs	sin datos	0.026% $ 0.002

0.7yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de UTRS no se considera experimentado ( 0.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Uri Geiger	Director	1.6yrs	sin datos	sin datos
Catherine Coste	Independent Director	3.6yrs	US$187.50k	0.067% $ 0.005
Daniel Cohen	Independent Director	1.6yrs	sin datos	0% $ 0

1.6yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de UTRS no se considera experimentada (1.3 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Minerva Surgical Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Minerva Surgical, Inc. Announces the Resignation of Jill D. Anderson from the Board of Directors

Minerva Surgical, Inc. Announces Resignation of Ross A. Jaffe from the Board and from the Compensation Committee of the Board

High number of new directors

Minerva Surgical, Inc. Announces Resignation of David M. Renzi from Board of Directors and as Chairman of its Nominating and Corporate Governance Committee

Minerva Surgical, Inc. Announces Management Changes

Minerva Surgical, Inc. Appoints Derrick Sung as Director

Recent updates

Minerva Surgical Files Form 15

Minerva Surgical, Inc.(OTCPK:UTRS) dropped from NASDAQ Composite Index

Minerva Surgical, Inc. Announces Voluntary SEC Deregistration and Nasdaq Delisting

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Minerva Surgical, Inc. Announces the Resignation of Jill D. Anderson from the Board of Directors

Minerva Surgical, Inc. announced that it expects to receive $20 million in funding from Accelmed Partners

Consensus EPS estimates upgraded to US$0.22 loss

Minerva Surgical, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Minerva Surgical, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Minerva Surgical, Inc. Announces Resignation of Ross A. Jaffe from the Board and from the Compensation Committee of the Board

Minerva Surgical Provides Revenue Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings released: US$1.18 loss per share (vs US$3.06 loss in FY 2021)

Minerva Surgical, Inc. announced that it has received $30 million in funding from Accelmed Partners, New Enterprise Associates, Inc.

High number of new directors

Minerva Surgical, Inc. Announces Resignation of David M. Renzi from Board of Directors and as Chairman of its Nominating and Corporate Governance Committee

Minerva Surgical Receives Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares

Minerva Surgical, Inc. Announces Management Changes

Minerva Surgical, Inc. announced that it expects to receive $30 million in funding from Accelmed Partners, New Enterprise Associates, Inc.

Consensus forecasts updated

Minerva Surgical, Inc. Provides Revenue Guidance for 2022

Third quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$5.00

Minerva Surgical Receives Notification Regarding Minimum Bid Price from the Listing Qualifications Department of the Nasdaq

Minerva Surgical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

U.S. Court of Appeals for the Federal Circuit Affirms Ruling on Minerva Surgical, Inc. and Hologic, Inc. Case

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There An Opportunity With Minerva Surgical, Inc.'s (NASDAQ:UTRS) 44% Undervaluation?

Minerva downgraded at JPMorgan citing lowered guidance

Minerva Surgical, Inc. Revises Revenue Guidance for the Year 2022

Minerva Surgical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Minerva Surgical, Inc. Appoints Derrick Sung as Director

Minerva Surgical, Inc.(NasdaqGM:UTRS) dropped from Russell Microcap Value Index

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Minerva Surgical, Inc. Provides Earnings Guidance for 2022

Minerva Surgical, Inc., Annual General Meeting, Jun 09, 2022

Minerva Surgical, Inc. Provides Revenue Guidance for the Full Year 2022

Minerva Surgical, Inc. (NASDAQ:UTRS) Just Reported Earnings, And Analysts Cut Their Target Price

Full year 2021 earnings: EPS exceeds analyst expectations

Minerva Surgical, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Minerva Surgical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2021

President recently bought US$123k worth of stock

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Minerva Surgical, Inc. Provides Revenue Guidance for the Full Year 2021

Minerva Surgical - Uterine Play For Sale

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad